| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
TARGUSinfo is a Vienna, VA-based company in the Software and Internet sector.
Empowering clients through trading and automation for global markets Each day the world's largest financial institutions trade billions on FXall
Horizons Co is a Columbus, OH-based company in the Software and Internet sector.
CitrusAd streamlines media sales and ad serving for more than half of the top 20 retailers in the world. Our Sponsored Product, Display Ad and Inventory Managent system is second to none